| Issue Date | Title | Author(s) |
| 2016 | The clinical utility of CA125/MUC16 in pancreatic cancer: A consensus of diagnostic, prognostic and predictive updates by the Chinese Study Group for Pancreatic Cancer (CSPAC) | Liu, Liang; Xiang, Jinfeng; Chen, Rufu; Fu, Deliang; Hong, Defei; Hao, Jihui; Li, Yixiong; Li, Jiangtao; Li, Shengping; Mou, Yiping; Mai, Gang; Ni, Quanxing; Peng, Li; Qin, Renyi; Qian, Hongang; Shao, Chenghao; Sun, Bei; Sun, Yongwei; Tao, Min; Tian, Bole; Wang, Hongxia; Wang, Jian; Wang, Liwei; Wang, Wei; Wang, Weilin; Zhang, Jun; Zhao, Gang; Zhou, Jun; Yu, Xianjun |
| Sep-2023 | Consensus of clinical diagnosis and treatment for non-functional pancreatic neuroendocrine neoplasms with diameter <2 cm | Wu, Wenming; Cai, Shouwang; Chen, Rufu; Fu, Deliang; Ge, Chunlin; Hao, Chunyi; Hao, Jihui; Huang, Heguang; Jian, Zhixiang; Jin, Gang; Li, Fei; Li, Haimin; Li, Shengping; Li, Weiqin; Li, Yixiong; Liang, Tingbo; Liu, Xubao; Lou, Wenhui; Miao, Yi; Mou, Yiping; Peng, Chenghong; Qin, Renyi; Shao, Chenghao; Sun, Bei; Tan, Guang; Wang, Huaizhi; Wang, Lei; Wang, Wei; Wang, Weilin; Wei, Junmin; Wu, Heshui; Wu, Zheng; Yan, Changqing; Yang, Yinmo; Yin, Xiaoyu; Yu, Xianjun; Yuan, Chunhui; Zhao, Yupei |
| 2017 | Efficacy and safety of weekly nab-paclitaxel plus gemcitabine in Chinese patients with metastatic adenocarcinoma of the pancreas: a phase II study | Xu, Ruihua; Yu, Xianjun; Hao, Jihui; Wang, Liwei; Pan, Hongming; Han, Guohong; Xu, Jianming; Zhang, Yanqiao; Yang, Shujun; Chen, Jia; Ying, Jieer; Dai, Guanghai; Li, Mingyu; Begic, Damir; Lu, Brian; Shen, Lin |
| 15-Feb-2022 | Integrated single-cell multiomics analysis reveals novel candidate markers for prognosis in human pancreatic ductal adenocarcinoma | Fan, Xiaoying; Lu, Ping; Wang, Hongwei; Bian, Shuhui; Wu, Xinglong; Zhang, Yu; Liu, Yang; Fu, Danqi; Wen, Lu; Hao, Jihui; Tang, Fuchou |
| 17-Apr-2020 | PD-L1 is a direct target of cancer-FOXP3 in pancreatic ductal adenocarcinoma (PDAC), and combined immunotherapy with antibodies against PD-L1 and CCL5 is effective in the treatment of PDAC | Wang, Xiuchao; Li, Xin; Wei, Xunbin; Jiang, Haiping; Lan, Chungen; Yang, Shengyu; Wang, Han; Yang, Yanhui; Tian, Caijuan; Xu, Zanmei; Zhang, Jiangyan; Hao, Jihui; Ren, He |
| 2015 | Should a standard lymphadenectomy during pancreatoduodenectomy exclude para-aortic lymph nodes for all cases of resectable pancreatic head cancer? A consensus statement by the Chinese Study Group for Pancreatic Cancer (CSPAC) | Liu, Chen; Chen, Rufu; Chen, Yingtai; Fu, Deliang; Hong, Defei; Hao, Jihui; Liu, Dawei; Li, Jiangtao; Li, Shengping; Li, Yixiong; Mai, Gang; Mou, Yiping; Ni, Quanxing; Peng, Li; Qian, Honggang; Qin, Renyi; Sun, Bei; Sha, Chenghao; Sun, Yongwei; Tian, Bole; Wang, Jian; Wang, Wei; Wang, Weilin; Zhao, Gang; Yu, Xianjun |
